MICHAEL JOHN TOMSICEK Insider Trading $CRSP CRISPR Therapeutics AG
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for MICHAEL JOHN TOMSICEK.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of MICHAEL JOHN TOMSICEK. MICHAEL JOHN TOMSICEK is Vice President, CFO in ABIOMED INC ($ABMD) and SVP & Chief Financial Officer in CUBIST PHARMACEUTICALS INC ($CBST) and Director in Milestone Pharmaceuticals Inc. ($MIST) and Chief Financial Officer in CRISPR Therapeutics AG ($CRSP).
MICHAEL JOHN TOMSICEK in CRISPR Therapeutics AG
Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of MICHAEL JOHN TOMSICEK: Chief Financial Officer
Holdings: 3,243 shares
Current Value: $51,077
Latest Transaction: Mar 12 2021
$CRSP Market Capitalization: $605.88M
$CRSP Previous Close: $15.75
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of MICHAEL JOHN TOMSICEK in CRISPR Therapeutics AG
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ABMD, CRSP, CBST, MIST
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12 2021 | CRSP | CRISPR Therapeutic ... | TOMSICEK MICHAEL JOHN | Chief Financial Off ... | Option Exercise | A | 0.00 | 9,000 | 0 | 9,000 | |
| Mar 12 2021 | CRSP | CRISPR Therapeutic ... | TOMSICEK MICHAEL JOHN | Chief Financial Off ... | Option Exercise | A | 133.88 | 25,360 | 3,395,197 | 25,360 | |
| Mar 12 2021 | CRSP | CRISPR Therapeutic ... | TOMSICEK MICHAEL JOHN | Chief Financial Off ... | Payment of Exercise | F | 124.15 | 1,352 | 167,851 | 1,891 | 3.2 K to 1.9 K (-41.69 %) |
| Mar 12 2021 | CRSP | CRISPR Therapeutic ... | TOMSICEK MICHAEL JOHN | Chief Financial Off ... | Buy | M | 0.00 | 2,833 | 0 | 3,243 | 410 to 3.2 K (+690.98 %) |
| Oct 06 2020 | CRSP | CRISPR Therapeutic ... | TOMSICEK MICHAEL JOHN | Chief Financial Off ... | Option Exercise | A | 86.75 | 11,666 | 1,012,026 | 11,666 | |
| Sep 03 2020 | CRSP | CRISPR Therapeutic ... | TOMSICEK MICHAEL JOHN | Chief Financial Off ... | Option Exercise | M | 17.75 | 12,000 | 213,000 | 156,000 | |
| Sep 03 2020 | CRSP | CRISPR Therapeutic ... | TOMSICEK MICHAEL JOHN | Chief Financial Off ... | Sell | S | 93.18 | 2,800 | 260,904 | 410 | 3.2 K to 410 (-87.23 %) |
| Sep 03 2020 | CRSP | CRISPR Therapeutic ... | TOMSICEK MICHAEL JOHN | Chief Financial Off ... | Sell | S | 92.23 | 6,400 | 590,272 | 3,210 | 9.6 K to 3.2 K (-66.60 %) |
| Sep 03 2020 | CRSP | CRISPR Therapeutic ... | TOMSICEK MICHAEL JOHN | Chief Financial Off ... | Sell | S | 91.39 | 2,800 | 255,892 | 9,610 | 12.4 K to 9.6 K (-22.56 %) |
| Sep 03 2020 | CRSP | CRISPR Therapeutic ... | TOMSICEK MICHAEL JOHN | Chief Financial Off ... | Buy | M | 17.75 | 12,000 | 213,000 | 12,410 | 410 to 12.4 K (+2,926.83 %) |
| Sep 03 2020 | CRSP | CRISPR Therapeutic ... | TOMSICEK MICHAEL JOHN | Chief Financial Off ... | Option Exercise | M | 17.75 | 12,000 | 213,000 | 156,000 | |
| Sep 03 2020 | CRSP | CRISPR Therapeutic ... | TOMSICEK MICHAEL JOHN | Chief Financial Off ... | Sell | S | 93.18 | 2,800 | 260,904 | 410 | 3.2 K to 410 (-87.23 %) |
| Sep 03 2020 | CRSP | CRISPR Therapeutic ... | TOMSICEK MICHAEL JOHN | Chief Financial Off ... | Sell | S | 92.23 | 6,400 | 590,272 | 3,210 | 9.6 K to 3.2 K (-66.60 %) |
| Sep 03 2020 | CRSP | CRISPR Therapeutic ... | TOMSICEK MICHAEL JOHN | Chief Financial Off ... | Sell | S | 91.39 | 2,800 | 255,892 | 9,610 | 12.4 K to 9.6 K (-22.56 %) |
| Sep 03 2020 | CRSP | CRISPR Therapeutic ... | TOMSICEK MICHAEL JOHN | Chief Financial Off ... | Buy | M | 17.75 | 12,000 | 213,000 | 12,410 | 410 to 12.4 K (+2,926.83 %) |
| Aug 05 2020 | CRSP | CRISPR Therapeutic ... | TOMSICEK MICHAEL JOHN | Chief Financial Off ... | Option Exercise | M | 17.75 | 12,000 | 213,000 | 168,000 | |
| Aug 05 2020 | CRSP | CRISPR Therapeutic ... | TOMSICEK MICHAEL JOHN | Chief Financial Off ... | Sell | S | 87.33 | 5,448 | 475,790 | 410 | 5.9 K to 410 (-93.00 %) |
| Aug 05 2020 | CRSP | CRISPR Therapeutic ... | TOMSICEK MICHAEL JOHN | Chief Financial Off ... | Sell | S | 86.25 | 6,552 | 565,128 | 5,858 | 12.4 K to 5.9 K (-52.80 %) |
| Aug 05 2020 | CRSP | CRISPR Therapeutic ... | TOMSICEK MICHAEL JOHN | Chief Financial Off ... | Buy | M | 17.75 | 12,000 | 213,000 | 12,410 | 410 to 12.4 K (+2,926.83 %) |
| Mar 12 2020 | CRSP | CRISPR Therapeutic ... | TOMSICEK MICHAEL JOHN | Chief Financial Off ... | Option Exercise | A | 0.00 | 8,500 | 0 | 8,500 | |
| Mar 12 2020 | CRSP | CRISPR Therapeutic ... | TOMSICEK MICHAEL JOHN | Chief Financial Off ... | Option Exercise | A | 44.67 | 35,000 | 1,563,450 | 35,000 | |
| Dec 05 2019 | CRSP | CRISPR Therapeutic ... | TOMSICEK MICHAEL JOHN | Chief Financial Off ... | Option Exercise | A | 0.00 | 20,000 | 0 | 20,000 | |
| Mar 07 2019 | CRSP | CRISPR Therapeutic ... | TOMSICEK MICHAEL JOHN | Chief Financial Off ... | Option Exercise | A | 40.87 | 75,000 | 3,065,250 | 75,000 | |
| Jun 15 2018 | CRSP | CRISPR Therapeutic ... | TOMSICEK MICHAEL JOHN | Chief Financial Off ... | Option Exercise | A | 59.31 | 20,760 | 1,231,276 | 20,760 | |
| Jun 15 2018 | CRSP | CRISPR Therapeutic ... | TOMSICEK MICHAEL JOHN | Chief Financial Off ... | Option Exercise | A | 59.31 | 20,760 | 1,231,276 | 20,760 | |
| Mar 09 2018 | CRSP | CRISPR Therapeutic ... | TOMSICEK MICHAEL JOHN | Chief Financial Off ... | Option Exercise | A | 51.49 | 25,000 | 1,287,250 | 25,000 | |
| Nov 14 2017 | CRSP | CRISPR Therapeutic ... | TOMSICEK MICHAEL JOHN | Chief Financial Off ... | Option Exercise | A | 17.75 | 180,000 | 3,195,000 | 180,000 |
Page: 1